



## 7th International Cancer Conference

'Enhancing Cancer Cure through Patient  
focused Healthcare and Research'

# cancerconference

### 13-15 May 2009



ST JAMES'S  
HOSPITAL

TRINITY  
COLLEGE  
DUBLIN



NATIONAL  
CANCER  
INSTITUTE



P  
R  
O  
G  
R  
A  
M  
M  
E



**7th International Cancer Conference**



**‘Enhancing Cancer Cure through Patient focused Healthcare and Research’**  
Institute of Molecular Medicine, St James’s Hospital, Dublin 8  
**13 - 15 May 2009**



### **CANCER 2009 WELCOME**

Welcome to **CANCER 2009, the International Cancer Conference**. This year we celebrate our 7<sup>th</sup> Anniversary and have assembled a high quality program ([www.cancerconference.ie](http://www.cancerconference.ie)) with international renowned leaders coming together to highlight the latest developments and challenges that we face to deliver 21<sup>st</sup> Century Medicine to Cancer Patients. The Conference Theme is “*Enhancing Cancer Cure through Patient focused Healthcare and Research*”

**CANCER 2009** will address key issues in cancer strategy, cancer care and cancer research, **placing the patient at the centre of a focused interdisciplinary approach** aimed at improving cancer outcomes. The Conference will discuss the key priorities at national and international levels, identifying appropriate solutions based on best international practice and examining how we can appropriately embed research within our health service. **Embracing all stakeholders** allows the delivery of the best care for cancer patients. This showcase of national and international leaders will critically review the latest developments **in translational cancer research, cancer systems, healthcare economics, radiation oncology and molecular imaging, cancer nursing, cancer biology and molecular medicine**, providing the ideal forum to discuss these important issues and highlight advances that have been made. As you can see, this Conference has something for everyone and I would encourage you and your colleagues to make a significant effort to attend this premier event. I would like to take this opportunity to thank my fellow members of the Scientific and Organising Committees. I would also like to acknowledge the generous support of our sponsors. I am extremely enthusiastic about the quality of the program and look forward to meeting you all in Dublin.

**Prof Mark Lawler**  
**On behalf of CANCER 2009 Scientific Committee**



## MESSAGE FROM THE MINISTER OF HEALTH AND CHILDREN



It is a significant pleasure for me to open the **7<sup>th</sup> International Cancer Conference** at the Institute of Molecular Medicine, St James’s Hospital and Trinity College Dublin. I would particularly like to acknowledge Prof Mark Lawler and the scientific committee for their significant efforts in organising this conference and in attracting such a distinguished panel of national and international speakers in cancer control and cancer research. The theme of this year’s conference is *“Enhancing Cancer Cure through patient focused Healthcare and Research”* and an exciting programme will examine the developments and challenges that we face to deliver 21<sup>st</sup> Century Medicine to Cancer Patients.

The sustained pursuit of knowledge across the continuum of cancer control that is demonstrated in the oncology community both on the island of Ireland and internationally is very impressive. This is reflected in the breadth of expertise at the conference and in the specialised themes to be addressed. Areas such as Translational Cancer Research are crucial to the delivery of new and innovative medicines to cancer patients. The economics of cancer are also a critical component to cancer care delivery, something that has been recognised in the recent award of Health Economics Fellowships by the Health Research Board.

We appreciate the support of the National Cancer Institute in the United States who have been contributed greatly to this Conference and have been important partners in the improvement of cancer services on both sides of the border, particularly in the facilitation of all Ireland participation in clinical trials. The Ireland/Northern Ireland/NCI Cancer Consortium has been an extremely beneficial interaction, providing the basis for a long-term partnership to improve cancer care delivery. Co-operation with our cancer colleagues in Northern Ireland is evidenced in the programme. Keynote speakers from major cancer institutions in Europe, will add significantly to the quality of the program.

I wish the conference every success and I hope that the speakers and participants alike and especially our visitors from abroad will enjoy their stay in our beautiful city.

**Minister Mary Harney, Minister for Health and Children**



## MESSAGE FROM THE DIRECTOR OF THE NCI, USA



It is with distinct honor that I welcome you to CANCER 2009, the 7<sup>th</sup> International Cancer Conference. While I regret that I am unable to attend this year’s conference, I share with our all-Ireland colleagues an enduring commitment to centering our cancer research efforts and cancer care strategies on the patient.

Over the past 70 years, the National Cancer Institute (NCI) has remained resolute in the global fight against cancer by fostering innovative research and increasingly effective cancer control interventions around the world. Through the Ireland-Northern Ireland-NCI Cancer Consortium, the NCI has worked closely for nearly a decade with the cancer research and public health communities on the island of Ireland to enhance cancer care and improve treatment through dedicated research. The collaborative spirit exemplified through the Consortium continues to provide a successful model for global cooperation, and CANCER 2009 will provide a glimpse of this cross-border partnership’s success.

This year, the NCI is proud to sponsor a special lecture on the opening day of CANCER 2009. Professor Hedvig Hricak, chair of the Department of Radiology at the Memorial Sloan-Kettering Cancer Centre in New York, a personal friend and loyal supporter of NCI, will present a talk entitled “Oncologic Imaging, Endless Horizons!” In addition, this year’s conference, for the first time, will feature an open public symposium, “**The Fight Against Cancer: Where Do We Stand?**”

As we continue to cultivate productive research relationships, our future success in defeating cancer can only be assured through a sustained, mutual commitment to cancer research. I look forward to forging ahead alongside our partners on the island of Ireland, further intensifying our research efforts to reduce the human toll of cancer, advance prevention measures, and ensure the best possible treatment outcomes for individuals affected by cancer across the globe.

Sincerely,

**Dr. John Niederhuber, Director, National Cancer Institute, Bethesda, USA**



## MESSAGE FROM THE IRISH CANCER SOCIETY



It is with great pleasure that we are a major sponsor of CANCER 2009, the International Cancer Conference, which takes place here in St James’s Hospital in Dublin. Cancer is an illness that affects large numbers of people, of all ages and backgrounds, and is feared by individuals and families alike. The latest data from the National Cancer Registry (NCR) states that 25,500 new cases of cancer were diagnosed in 2005. Furthermore, the Registry estimates that approximately 30,000 new cases

of cancer will be diagnosed in 2010 and 42,000 cases in 2020, which represents a 62 per cent increase overall from 2005 to 2020.

Over this year and 2010, the Irish Cancer Society (ICS) will focus on cancer prevention, early detection and fighting cancer. We will implement three distinct programme areas to achieve our goals: advocacy, cancer services and research. In cancer prevention, we will work to establish an environment that fully embraces a zero tolerance attitude to smoking in young people. Our primary objective will be to reduce the numbers of young people taking up smoking from 18% to 10%. The latest data from the NCR shows that 2,184 new cases of bowel cancer were diagnosed in 2005 and approximately 50% of these patients were diagnosed at Stage 3 and 4 (advanced stages). In the early detection arena, we will therefore work to reduce the numbers of people presenting with Stage 3 bowel cancer by 10% per annum and reduce mortality from colorectal cancer in those over 50 years of age.


In the fighting cancer arena, our main goal will be to ensure that every member of the Irish public, regardless of age, sex, social and ethnic background, has access to the information and support they need to enhance their physical, emotional and spiritual well-being as they travel the cancer journey. The Society is the largest voluntary funder of cancer research in Ireland. Research projects aimed at finding better ways of diagnosing and treating cancer are a vital element in the fight against cancer. In 2008, the ICS awarded its first ever fellowship grants to two cancer researchers, both based in Ireland. Fellowships fund people rather than projects and are designed to provide support for excellent people working in cancer research in Ireland. The Society also part funds activities of the All Ireland Co-operative Oncology Research Group (ICORG). ICORG is an all-Ireland voluntary organisation which brings leading edge cancer clinical trials to patients with cancer at hospital sites throughout the country. By 2010 over 5% of patients with cancer in Ireland will participate in clinical trials.

We are delighted to be supporting CANCER 2009 where many of these issues will be discussed and debated.

**Mr John McCormack, CEO Irish Cancer Society**



**Tracy’s Kids: The Art of Healing**  
**Venue: Main Foyer and Corridor A**  
**St James’s Hospital Dublin**  
**Tuesday 12th May 6pm**



**Can Art help people with cancer?  
We think it can!**

**Come see this very special exhibition,  
showcasing the work of children with cancer**

The NCI/Tracy’s Kids International Art Exchange is a collection of 207 drawings by kids with cancer, produced while they were patients in Cancer Centres in the US and the Middle East (Jordan, Israel, Egypt, Turkey). Created during 2007 and 2008 in response to the theme “The day I will never forget . . .” the exhibition is visiting Ireland as part of CANCER 2009 and will be exhibited from Tuesday 12th May - mid July.

This exhibition is linked to an Art Therapy program which has been in operation in the Lombardi Cancer Centre in Georgetown, Maryland since 1992. The Program and this Exhibition aims to use art therapy to help young patients to develop creative communication skills that will help them to be emotionally equipped to fight cancer while they are being treated and also to be psychologically prepared for when they are cancer free.

We hope that this Exhibition, as well as showing the courage and talent of the children who have produced such wonderful and life affirming pictures, will also provoke debate on the role of art therapy and art intervention for both children and adults in Ireland.

For more information visit <http://www.cancerconference.ie> and <http://www.tracyskids.org>





## WEDNESDAY 13<sup>TH</sup> MAY 2009

### St James’s Hospital - Belfast City Hospital – National Cancer Institute Forum EMBEDDING TRANSLATIONAL MEDICINE IN CANCER CARE

9.30 Registration for CANCER 2009

9.40 Welcome and Opening of Forum

#### **SESSION I: “INTEGRATING BIOLOGY, PATHOLOGY AND CANCER RISK”**

**Chairpersons:** Prof Ken O Byrne, St James’s Hospital and Trinity College Dublin, Ireland; Prof Conor O’Keane, Mater Misericordiae University Hospital and University College Dublin, Ireland

#### **9.45 Introduction**

Prof Ken O Byrne, St James’s Hospital and Trinity College Dublin, Ireland

#### **9.50 “MicroRNAs – potential biomarkers in cancer or red herrings?”**

Prof Orla Sheils, St James’s Hospital and Trinity College Dublin, Ireland

#### **10.15 “Stem cells in the prevention of Barrett’s metaplasia; the root of cancer”**

Prof Janusz Jankowski, Department of Clinical Pharmacology, University of Oxford, UK

#### **10.45 “There may be trouble ahead” – Assessing genetic risk of lung cancer”**

Prof Tim Eisen, Cambridge Cancer Centre, University of Cambridge, UK

#### **11.15 Round Table Discussion**

**Moderator:** Prof Conor O’Keane, Mater Misericordiae University Hospital and University College Dublin

#### **11.25 Coffee and Exhibition/ Poster Viewing**



#### **SYMPOSIUM I: NEW FRONTIERS IN COLORECTAL CANCER**

**Chairpersons:** Prof Elaine Kay, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland; Dr John Kennedy, St James’s Hospital, Dublin, Ireland

#### **11.55 Introduction**

Prof Elaine Kay, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland

#### **12.00 “Tailoring treatment to your patients; molecular medicine takes centre stage”**

Professor Sabine Tejpar, University Hospital Gasthuisberg, University of Leuven, Belgium

#### **12.30 Tailoring surgery to your patients: minimally or maximally invasive?**

Prof Ronan O Connell, St Vincent’s University Hospital and University College Dublin, Ireland

#### **12.55 Round Table Discussion**

**Moderator:** Dr John Kennedy St James’s Hospital, Dublin, Ireland

#### **13.05 End of Symposium**

#### **13.05 Lunch and Exhibition/ Poster Viewing**



## **SESSION II: “CANCER THERAPEUTICS IN THE 21<sup>ST</sup> CENTURY”**

**Chairpersons;** *Dr Robert O Connor, Chairperson, Translational Disease Specific Subgroup, All Ireland Cooperative Oncology Research Group; Dr Ray McDermott, Adelaide and Meath incorporating the National Childrens Hospital (AMNCH), Tallaght, Dublin, Ireland*

### **13.50 Introduction**

Dr Robert O Connor, Chairperson, Translational Disease Specific Subgroup, All Ireland Cooperative Oncology Research Group

### **13.55 “FKBPL: a novel anti-angiogenic protein that targets CD44”**

Dr Tracey Robson, School of Pharmacy, Queens University Belfast, Northern Ireland

### **14.20 Casein kinase, a bifunctional regulator of NF-kB and lymphoma cell survival; is this a new potential target for cancer therapeutics?**

Dr Mike Lenardo, Chief, Molecular Development of the Immune System Section, National Institutes of Health, Washington, USA

### **14.50 “Epigenetic targeting and its role in cancer therapy”**

Prof Robert Browne, Professor of Translational Oncology, Imperial College London, UK

### **15.20 “Translational Research - the appliance of science!”**

Prof Herbie Newell, Professor of Cancer Therapeutics, Northern Institute of Cancer Research, University of Newcastle, UK

### **15.45 Round Table Discussion**

**Moderator:** *Prof Cormac Taylor, University College Dublin, Ireland*

### **15.55 Coffee and Exhibition/ Poster Viewing**



### **16.15 THE NATIONAL CANCER INSTITUTE LECTURE**

*Introduced by Dr Jim Meaney, Director, Centre for Advanced Medical Imaging*

#### **“Oncologic Imaging, Endless Horizons !”**

Prof Hedvig Hricak, Chair, Department of Radiology, Memorial Sloan-Kettering Cancer Centre, New York, USA

### **16.50 End of Forum**





## SESSION III: PUBLIC SYMPOSIUM

### THE FIGHT AGAINST CANCER; WHERE DO WE STAND?

Help us to help you find out more about cancer?

Can you reduce your risk of getting this disease?

*Chairpersons: Dr John Bowman, Broadcaster and Author, Dr Muiris Houston, Irish Times*

#### 16.30 Registration

#### 17.00 Launch of Symposium

Councillor John Gallagher, Dublin City Council , Dr Muiris Houston, Irish Times

#### 17.10 *Understanding cancer; is it all in your genes?*

Prof Mark Lawler, St James’s Hospital and Trinity College Dublin, Ireland

#### 17.35 *Man, Woman, Child; perspectives on cancer risk and cancer care*

Prof Ralph De Vere White	Prof John Crown	Dr Joe Simonne
UC Davis Cancer Centre	St Vincent’s University	University of Florida-Shands
California, USA	Hospital, Dublin	Cancer Center, Florida, USA

#### 18.55 *How can we stop ourselves from getting cancer?*

Dr Fenton Howell, Health Service Executive, Ireland

#### 19.20 *The Future of Cancer Medicine*

Prof Patrick Johnston, Queens University Belfast, Northern Ireland

#### 19.50 Questions and Answers

**Additional Panellists:** *Dr Tony O Brien, National Cancer Screening Service Board, Mr Thomas Lynch, St James’s Hospital, Ms Kathleen O Meara, Irish Cancer Society, Prof Owen Smith, Our Lady’s Childrens Hospital, Crumlin.*

#### 20.15 Refreshments



## THURSDAY 14<sup>TH</sup> MAY

### 8.30 Registration for CANCER 2009



#### **SESSION IV: CANCER STRATEGY: HOW, HOW FAR, HOW MUCH?**

*Chairpersons: Prof John Reynolds, St James’s Hospital and Trinity College Dublin, Ireland; Dr Davida De La Harpe, Health Services Executive, Ireland*

#### **8.50 Introduction**

Prof John Reynolds, St James’s Hospital and Trinity College Dublin, Ireland

#### **8.55 “Cancer Control, the challenge for Healthcare Systems”**

Ms Mary Jackson, Cancer Policy Unit, Department of Health and Children, Ireland

#### **9.15 “Cancer Clinical Trials in Ireland; moving forward”.**

Dr Paul Browne, Chairperson, All Ireland Co-operative Oncology Research Group

#### **9.25 OPENING ADDRESS**

**Mr Ian Carter, CEO, St James’s Hospital, Dublin, Ireland**

**Prof Tom Keane, Interim Director, National Cancer Control Programme, Ireland**

**Ms Mary Harney, TD, Minister for Health and Children, Ireland**

**Prof Dermot Kelleher, Head of School of Medicine and Vice Dean for Medical Affairs, Trinity College Dublin, Ireland**

#### **10.10 “The Many Faces of Quality Cancer Care”**

Dr Joe Simone, University of Florida-Shands Cancer Center, Florida, USA

#### **10.45 “Team Science; The Core of a Functioning Cancer Program”**

Prof Ralph DeVere White, UC Davis Cancer Centre, California, USA

#### **11.20 Round Table Discussion**

*Moderator: Prof Luke Clancy, Director, TobaccoFree Research Institute, Dublin, Ireland*

#### **Coffee and Exhibition/ Poster Viewing**



#### **12.00 KEYNOTE ADDRESS: The Health Research Board Lecture**

*Introduced By Mr Enda Connolly, CEO Health Research Board, Dublin, Ireland*

#### **“The cost of cancer and access to innovative drugs in oncology”**

Prof David Khayat, Head, Department of Medical Oncology, Salpetriere Hospital; Honorary President, French National Cancer Institute, Paris, France



## 12.40 Lunch and Exhibition/ Poster Viewing

### SESSION V: CANCER: WHO’S AT RISK?

*Chairpersons: Dr Anna Gavin, Director, Northern Ireland Cancer Registry, Belfast, Northern Ireland; Prof Shane Allwright, Department of Public Health and Primary Care, Trinity College Dublin, Ireland*

#### 13.40 Introduction

Dr Anna Gavin, Director, Northern Ireland Cancer Registry, Belfast, Northern Ireland

#### 13.45 “The causes and prevention of breast cancer”

Prof Valerie Beral, Professor of Cancer Epidemiology, University of Oxford, UK

#### 14.15 “Work and cancer - the case of the lymphomas”

Prof Anthony Staines, Professor of Health Systems Research, Dublin City University, Ireland

#### 14.40 “Obesity and Cancer, prevention lessons learned from tobacco!”

Prof Jane Wardle, Health Behaviour Unit, University College London, UK



### SESSION VI: CANCER STRATEGIC DEVELOPMENT AWARD

*Chairperson: Prof Mark Lawler, St James’s Hospital and Trinity College Dublin, Ireland*

#### 15.20 Cancer Strategic Development Award Lecture

##### “Cancer Developments in the last 2 decades; how have we done?”

Prof Des Carney, Mater Misericordiae University Hospital and University College Dublin, Ireland

## 16.00 Coffee and Exhibition/ Poster Viewing

### SESSION VII: IMPROVING THE PATIENT’S EXPERIENCE

*Chairpersons: Ms Barbara Cosgrave, ARC Cancer Support Group, Dublin, Ireland; Ms Mairead Lyons, Head of Services, Irish Cancer Society, Ireland*

#### 16.30 Introduction

Ms Barbara Cosgrave, ARC Cancer Support Group, Dublin, Ireland

#### 16.35 “Managing Cancer-Related-Fatigue: A home-based programme using cognitive behavioural techniques.”

Dr Sonya Collier, Psychological Medicine Service, St James’s Hospital, Dublin, Ireland

#### 16.50 “The Allotment Project’: An Innovative Psychological Service model for Men with Cancer.”

Dr Paul D’Alton, Psycho-Oncology Service, St Vincent’s University Hospital, Dublin, Ireland

#### 17.05 Special Lecture

##### “Cure is not Enough; Long Term Follow-up for Childhood Cancer Survivors.”

Prof Aziza Shad, Lombardi Comprehensive Cancer Centre, University of Georgetown, Washington DC, USA



## **SESSION VIII: EUROLIFE DISTINGUISHED FACULTY LECTURE**

**Chairperson:** Prof Dermot Kelleher, Head of School of Medicine and Vice Dean for Medical Affairs, Trinity College Dublin, Ireland

### **17.45 Introduction**

Prof Frank Gannon, Director General, Science Foundation Ireland.

### **17.50 “How I moved malignant diseases in the nuclear receptor field”**

Prof Pierre Chambon, Institute of Genetics and Molecular and Cellular Biology, University of Strasbourg, France

### **18.40 End of Day 2**

### **19.30 Reception, The Crypt, Christchurch Cathedral**

## **FRIDAY 15<sup>TH</sup> MAY 2009**

### **08.30 REGISTRATION AND EXHIBITION/ POSTER VIEWING**

## **SESSION IX; SPECIAL SYMPOSIUM: EMPHASISING THE IMPORTANCE OF NURSING IN CANCER CARE (Concurrent session)**

**Chairpersons:** Ms Joan Kelly, Nursing Services Manager, Irish Cancer Society, Ireland; Mr Paul Gallagher, Director of Nursing, St James’s Hospital, Dublin, Ireland

### **8.45 Introduction**

Ms Margaret Codd, Directorate Nurse Manager, St James’s Hospital Dublin, Ireland

### **8.50 “Delivering advanced oncology nursing practice”**

Dr Janice Richmond, Advanced Practitioner Cancer, Letterkenny General Hospital, Donegal, Ireland

### **9.15 “Breast cancer review clinics; benefits and realities”**

Dr Eilis McCaughan, Reader in Cancer Care, Institute of Nursing Research, University of Ulster, Coleraine, Northern Ireland

### **9.40 “Integration of Clinical Pharmacy and an Oncology-Haematology Day Care Unit.”**

Ms Fionnuala King, Chief II Pharmacist, St James’s Hospital, Dublin, Ireland

### **9.55 “The impact of the late effects clinic on survivorship post allogeneic stem cell transplantation.”**

Ms Mairead Ni Chonghaile, Bone Marrow Transplant Co-ordinator, St James’s Hospital, Dublin, Ireland

### **10.10 “The Power of Art: Art Therapy in Pediatric Hematology-Oncology.”**

Ms Tracy Councill, Lombardi Comprehensive Cancer Centre, University of Georgetown, Washington DC, USA

### **10.35 Round Table Discussion**

**Moderator:** Ms Joan Kelly, Nursing Services Manager, Irish Cancer Society

### **10.45 End of Session**



## **SESSION X: CANCER CHEMICAL BIOLOGY; PROVIDING THE IMPETUS FOR CANCER DRUG DEVELOPMENT (Concurrent session)**

*Chairpersons: Dr David Lloyd, Trinity College Dublin, Ireland; Prof Corrado Santocanale, National University of Ireland, Galway, Ireland*

### **8.55 Introduction**

Dr David Lloyd, Dean of Research, Trinity College Dublin, Ireland

### **9.00 “Cancer Drug development; the industry perspective!”**

Dr Damian O Connell, Executive Director, Pfizer Clinical R + D Sandwich, UK and Chairperson, Molecular Medicine Ireland Board

### **9.30 SPECIAL LECTURE**

#### ***“Can we really design drugs?”***

Prof Rod Hubbard, University of York, UK

### **10.10 “Improving and extending therapeutic benefit through formulation development”**

Dr John Fox, Merrion Pharmaceuticals, Dublin, Ireland

### **10.20 Round Table Discussion**

*Moderator: Prof Corrado Santocanale, National University of Ireland, Galway, Ireland*

### **10.30 Coffee and Exhibition/ Poster Viewing**

## **SESSION XI: FRONTIERS IN RADIATION ONCOLOGY**

*Chairpersons: Prof Donal Hollywood, St Lukes Hospital, St James’s Hospital and Trinity College Dublin, Ireland; Prof Frank Sullivan, University College Hospital, Galway Ireland*

### **10.55 Introduction**

Prof Donal Hollywood, St Lukes Hospital, St James’s Hospital and Trinity College Dublin

### **11.00 “Functional molecular prediction and targeting of radiotherapy response”**

Prof Anne Hansen Ree, Professor of Oncology, Norwegian Radium Hospital, University of Oslo, Norway

### **STATE OF THE ART LECTURE**

#### **11.35 “Integrating biology and high technology in modern radiation oncology”**

Prof Michael Baumann, Professor of Radiation Oncology, University of Dresden, Germany and President European CanCer Organisation

## **SYMPOSIUM II: DISSECTING THE BIOLOGY OF CANCER**

*Chairpersons: Prof Rosemary O Connor, Department of Biochemistry, University College Cork, Ireland; Dr Adrian Bracken, Smurfit Institute of Genetics, Trinity College Dublin and Adelaide and Meath incorporating National Children’s Hospital, Tallaght, Dublin, Ireland.*

### **12.15 Introduction**

Prof Rosemary O Connor, Department of Biochemistry, University College Cork, Ireland



## **12.20 State of the Science Lecture**

***“Pro-Tumor Immunity and breast cancer development”***

Prof Lisa Coussens University of California, San Francisco, USA

## **13.00 End of Symposium**

## **13.00 Lunch and Exhibition/Poster Viewing**

### **13.45 KEYNOTE LECTURE**

*Introduced by Sheila O’Malley, Chief Nursing Officer Department of Health and Children, Ireland*

***“The role of the cancer nurse in research and clinical care”***

Prof Jessica Corner, Head of the School of Health Sciences, University of Southampton, UK



### **14.20 SESSION XII: IRISH CANCER SOCIETY LECTURE**

Introduced by Mr John Mc Cormack, CEO, Irish Cancer Society

***“Clinical Research Networks; empowering better care for cancer patients”***

Prof Peter Selby, Professor of Cancer Medicine, University of Leeds, UK

## **14.50 CONCLUDING REMARKS AND END OF MEETING**



**cancerconference**



## CANCER STRATEGIC DEVELOPMENT AWARD




**Prof Des Carney** is the 5<sup>th</sup> Recipient of the **Cancer Strategic Development Award** for his contribution to the development of cancer care and cancer research on the island of Ireland. His pioneering role in lung cancer research, recognised by a number of international awards, his leadership in developing a viable strategy for cancer care in Ireland, together with his huge commitment to cancer support groups such as the Irish Cancer Society and his pivotal role in the establishment of the ARC Cancer Support Service, have made a significant difference to cancer care and cancer research on this island. Prof Carney will be presented with the Award at **CANCER 2009** on Thursday 14<sup>th</sup> May 2009 at 15.20 where he will deliver the annual Cancer Strategic Development Award Lecture entitled “**Cancer Developments in the last 2 decades; how have we done?**”

**The Cancer Strategic Development Award** which is linked to *the International Cancer Conference* aims to recognise an individual or group of individuals who have made a significant strategic contribution in the area of cancer care, cancer prevention, cancer research or cancer related healthcare issues on the island of Ireland. It was established in 2005 and previous recipients of the award were:



**2005:** *Minister Micheal Martin, TD*, for his role while Minister of Health and Children in promoting cancer prevention by the introduction of the Smoking Ban (29<sup>th</sup> March, 2004). The recognised success of the Smoking Ban in Ireland has prompted many other countries to implement similar legislation, placing Ireland at the core of a significant international health care strategic development.



**2006:** *Prof Edison Liu* (currently Executive Director, Genome Institute of Singapore) for his role in helping to establish the *Ireland Northern Ireland National Cancer Institute Consortium* while Deputy Director of the National Cancer Institute. The Memorandum of Understanding was signed in Stormont Castle in Belfast in 1999, leading to a series of initiatives in cancer care, clinical trials, cancer education and cancer prevention which have generated significant benefit for the Cancer community on the island of Ireland

**2007:** *Prof Peter Daly*, former Consultant Oncologist, St James’s Hospital and Associate Professor of Oncology at Trinity College Dublin for his significant contribution to the development of oncology services, oncology research and oncology training on the island of Ireland. He is a founder member of the Irish Society of Medical Oncology and the Irish Clinical Oncology Research Group. He served on the first committee of the NCI / Ireland / Northern Ireland Cancer Consortium and developed cancer services as well as training and education opportunities on the island of Ireland. He also played a pivotal role in the establishment of adult genetic cancer services in Ireland.



**2008:** *Prof Patrick Johnston*, currently Head of the School of Medicine, Queens University Belfast for his pioneering work on cancer care and cancer research on the island of Ireland. His role in the establishment of the *Ireland Northern Ireland National Cancer Institute Consortium*, together with his scientific leadership in the establishment of both the Clinical Cancer Centre at Belfast City Hospital and the Centre for Cancer Research and Cellular Biology at Queens University Belfast are shining beacons of the type of strategic drive that is required to provide world class centres in cancer care and cancer research on this island.

**CANCER 2009 BIOGRAPHIES**



**Kenneth O'Byrne** is a Consultant Medical Oncologist with a particular interest in the management of thoracic malignancies. He is clinical director of the HOPE directorate at St James's Hospital and clinical professor at Trinity College, Dublin. Prof O'Byrne qualified from University College, Dublin (UCD), completed his higher professional training in oncology at the Churchill Hospital, Oxford and subsequently worked as a consultant and senior lecturer in medical oncology at the University Hospitals of Leicester NHS Trust and University of Leicester before returning to Dublin in 2003. Prof O'Byrne is a founder member and president of the British Thoracic Oncology Group and British Mesothelioma Interest Group. Since returning to Dublin Prof O'Byrne has set up the Thoracic Oncology Research Group based on the St James's Hospital Campus. The group has an interest in carcinogenesis, identification of novel biomarkers and novel targeted therapy in lung cancer and mesothelioma.



**Connor O'Keane** is Consultant Pathologist, Mater Misericordiae University Hospital and Associate Clinical Professor of Pathology, University College Dublin. His diagnostic tumour cell specialty interests include bone and soft tissue pathology, head and neck pathology and neoplastic and inflammatory dermatopathology. He is an active member of the Prostate Cancer Consortium. He is currently Dean of the Faculty of Pathology, Royal College of Physicians of Ireland and Chairman of the Medical Board, Mater Misericordiae University Hospital.



**Orla Sheils** is Associate Professor of Molecular Pathology and Lecturer in Medical Jurisprudence at TCD. She is based in St. James's Hospital working between the IMM and newly refurbished Sir Patrick Dun Research labs. She received her PhD from Trinity College exploring novel prognostic markers in thyroid neoplasia. The underlying theme of her research is to understand the causes and molecular basis of the development of disease, with particular reference to cancer, and to apply this knowledge to improving disease prevention, detection, diagnosis and treatment. She was awarded a Masters in Medical Law and Ethics at King's College London and has helped remodel undergraduate medical law teaching at TCD.



**Janusz Jankowski** is a recognised leader in mucosal biology, translational medicine and cancer prevention. In recognition of these achievements, he has won several prestigious prizes most notably the Sir Avery Jones Prize and the recipient of the Sir James Black Professorship. He trained first in Gastroenterology at the Universities of Glasgow and Dundee, undertaking population and translational research in oesophageal cancer. Following this, he worked on adhesion biology in colorectal cancer at the University of London (UL). He was awarded a travelling Betz Fellowship to work in the University of California, San Francisco. He returned to the UK to Professorship at the University of Birmingham, and as Department Head to the University of Leicester. He has now returned to UL to one of the strongest GI Research Units in the world. His clinical passion is being a therapeutic gastroenterologist and clinical trialist He also has a passion for vegetarian food with his speciality the 'Stanislaw Stack' (3 courses and 5 tastes-in-one meal). Janusz is happily married

(although he can't speak for his wife and three children).



**Tim Eisen** is Professor of Medical Oncology in Cambridge He was appointed chairman of the NCRI Lung Clinical Studies Group in 2004 and is a trustee of Kidney Cancer UK. He trained at the Middlesex Medicine Hospital School, London and the University of Cambridge School of Medicine. He was a clinical research fellow at the Marie Curie Research Institute in Surrey, completing a PhD in the molecular biology of melanoma. He was Senior Lecturer in Medical Oncology at University College London and the North Middlesex Hospital before moving to the Royal Marsden Hospital. In 2002, he became a fellow of the Royal College of Physicians.



**Elaine Kay** is a Consultant Histopathologist in Beaumont Hospital, Dublin and Professor of Pathology at the Royal College of Surgeons in Ireland. She has served on the Board of the Faculty of Pathology since 1996 and was the National Specialty Director for Histopathology training in the Republic of Ireland. She has an active research interest in solid organ malignancies with particular focus on markers with diagnostic utility and on markers of disease progression and response to treatment. She is currently a member of the Strategic Advisory Group of the NCI All Ireland Consortium.



**John Kennedy** holds the position as Consultant Medical Oncologist at St James’s Hospital and St. Lukes Hospital and Director of the Cancer Clinical Trials Consortium at St James’s Hospital. Dr. Kennedy did his undergraduate degree at Trinity College Dublin where he won the University Gold Medal in 1983. His training took him from Ireland to the United States where he began a Clinical Fellowship in Oncology at Johns Hopkins University in Baltimore and rose to the position of Associate Professor of Oncology before returning to Ireland in 1998. He is past Chairman of the Irish Clinical Oncology Research Group (ICORG), and Chairman of the Medical Committee of the Irish Cancer Society. His major research interest is in breast cancer.



**Sabine Tejbar** trained in Internal Medicine and Gastroenterology and received a Ph.D in the program of Molecular Oncology at the Center for Human Genetics, KULeuven, In 2003 she became Associate Professor in the Dept of Gastroenterology, Digestive Oncology Unit, UZ Leuven. She combines clinical and research work (Senior Clinical Investigator of the Fund for Scientific Research (Belgium)) , with a focus on basic and translational research in colorectal cancer. Her main research projects involve prognostic markers in adjuvant colorectal cancer and predictive markers for efficacy of EGFR inhibition.



**Ronan O’Connell** is Professor of Surgery and Consultant Surgeon at St Vincent’s University Hospital since September 2007. He was previously Senior Lecturer in Surgery at the Royal London Hospital, consultant surgeon at the Mater Misericordiae University Hospital and Newman Clinical Research Professor at UCD. In 2009, he was appointed Head of Surgery and Surgical Sciences at University College Dublin. Prof O’Connell is secretary of the European Association of Coloproctology. Prof O’Connell has published widely on colorectal cancer, IBD and pelvic physiology. He is a former editor of the British Journal of Surgery.



**Robert O’Connor**, Ph.D., is a Senior Programme Leader in Translational Cancer Pharmacology, at the National Institute for Cellular Biotechnology, Dublin City University. His research focuses on investigating methods to improve the activity of cancer drug treatments using biological and analytical methodology, with particular emphasis on resistance mechanisms in tumours. Through collaboration with a number of clinicians, this research has led to clinical trial testing (phase I and II) in a number of malignancies. Dr. O’Connor is a council member of the Irish Association for Cancer Research (IACR) and Chairman of the Translational group within the All-Ireland Cooperative Oncology Group (ICORG).




**Tracy Robson** obtained her PhD in Molecular Radiation Science from Imperial College London. Her first academic post was as Lecturer in Radiation Science at the University of Ulster. She moved to the School of Pharmacy, Queen’s University Belfast as Reader in Molecular Pharmacology. Her main research focus is the development of novel approaches for sensitizing tumours to both radio and chemotherapy. More recently, her research involves the identification and functional characterisation of genes that alter tumour response to anti-cancer agents. She cloned and is characterizing a novel human gene that alters tumour radiosensitivity and cell growth. She is now leading its development as a novel peptide therapeutic, in collaboration with Almac Discovery, Northern Ireland.



**Robert Brown** is Professor of Translational Oncology at the Department of Oncology at Imperial College London and the Section of Medicine at The Institute of Cancer Research. He graduated from Edinburgh University and did his PhD at the MRC Radiobiology Unit, Harwell. Following a postdoctoral fellowship at the German Cancer Research Centre Heidelberg, he worked at the Beatson Laboratories, Glasgow becoming Director of Laboratory Research in the Centre for Oncology and Applied Pharmacology before moving to his current post. Professor Brown’s work focuses on epigenetics and drug resistance research, with a particular focus on ovarian cancer, but includes breast and lung cancers. Professor Brown examines how tumours acquire resistance to chemotherapy and approaches to improving treatment by overcoming drug resistance.



**Herbie Newell** is Professor of Cancer Therapeutics at Newcastle University, and was Director of Translational Research at Cancer Research UK from 2006 to 2009, and interim Executive Director of Clinical and Translational Research in 2007/8. He is Past-Chairman of the British Association for Cancer Research and of the Laboratory Research Division of the EORTC. Professor Newell was involved in the development of the licensed agents carboplatin (Paraplatin) and ralitrexed (Tomudex), and is currently working on the discovery of molecularly-targeted anticancer drugs.



**Hedvig Hricak** is Chairperson of the Department of Radiology at Memorial Sloan-Kettering Cancer Center (MSKCC) and Professor of Radiology at the Weill Medical College of Cornell University. She earned her M.D. degree from the University of Zagreb and her Ph.D from the Karolinska Institute. Before coming to MSKCC, she was a professor of radiology, radiation oncology, urology and gynecology at the University of California at San Francisco . Dr. Hricak’s career in research, education and patient care has always focused on oncology. She helped develop the use of ultrasound, MRI and CT for gynecological cancer, and the use of MRI and MR spectroscopy for prostate cancer. Dr. Hricak has received numerous awards, including the Marie Curie Award from the Society of Women in Radiology, the gold medal of the International Society for Magnetic Resonance in Medicine, the gold medal of the Association of University Radiologists, the Beclere medal of the International Society of Radiology and the Morocco Medal of Merit.



**John Bowman** is a broadcaster and historian. He presents current affairs and historical programmes on RTE radio and television.



**Muiris Houston** undertook general practice training following his graduation from Trinity College Dublin in 1985. He then took up the post of inaugural medical director of St Francis Home Care Team. He worked as a GP in Ballymun and Finglas, in addition to working as an occupational physician and as part-time lecturer (Communication Skills) at the Department of General Practice at RCSI and for six years was CME tutor for the Irish College of General Practitioners for counties Meath & Louth. In 2000 he was appointed medical correspondent of **The Irish Times**, and was awarded Medical Journalist of the Year in 2001 and 2002. He is regular commentator on health matters on national and regional radio.




**Mark Lawler** is Associate Professor in Experimental Haematology/ Oncology, TCD and Chief Molecular Geneticist at St James’s Hospital. He has an active research group working on the genetic basis of cancer, with emphasis on translating this knowledge to new diagnostics and novel anti-cancer approaches. He has been honoured with numerous awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the Ulster Cancer Foundation Prize and he has received both the St Lukes Medal and the Graves Medal for research. He is currently President of the Irish Association for Cancer Research. He is founder and Chairperson of the highly successful Cancer Conference which has now become an annual event on the calendar. He is firmly committed to outreach and has participated in a number of community initiatives including “Your Health is your Wealth” and “Wise up! Its your life too!”.



**Ralph W. deVere White** is a professor of urology and director of the UC Davis Cancer Center, California. He received his medical degree from University College Dublin and completed an internship and residencies in surgery and urology at St. Vincent’s Hospital and at Duke University Medical Center in Durham, N.C. He is president of the Society of Urologic Oncology, the leading organization dedicated to developing new treatment strategies for urologic cancers. He is investigating the genetic mistakes that give rise to prostate cancer, the mechanisms that make some prostate cancers more virulent than others, and new methods of diagnosing and treating prostate cancer. Dr. deVere White has been named multiple times as one of “The Best Doctors in America.” He is one of four urologists serving as a volunteer consultant to the American Cancer Society’s on-line “Experts Answers” bulletin board for questions about prostate cancer.



**John Crown** is a Consultant Medical Oncologist at St Vincent’s University Hospital. A graduate of University College Dublin in 1980, he also received his medical training at the State University of New York. He completed his fellowship training at Mount Sinai Medical Center and at Memorial Sloan Kettering Cancer Center, both in New York. He also served as assistant professor at Cornell University Medical College before returning to Ireland to take up his consultant post at St Vincent’s and St Luke’s/St Anne’s Hospitals in Dublin. He is Thomas Baldwin Research Chair in Translational Cancer Research (Dublin City University). He is internationally recognized for his progressive research into improving the effects of chemotherapy dosage on cancer patients and has received a merit award from the European Society for Medical Oncology for his work in breast cancer research — the first Irish oncologist to have received such recognition.



**Aziza Shad's** world-renowned work in pediatric cancer research and clinical treatment has spanned more than 25 years and several continents. She is director of Georgetown University Hospital's Division of Pediatric Hematology/Oncology, Blood and Marrow Transplantation at the Lombardi Comprehensive Cancer Center She founded the Pediatric Cancer Survivorship Clinic at Georgetown University Hospital to provide ongoing care for her patients. Dr. Shad published a guide for pediatric cancer survivors and their families titled, "The Next Step: Crossing the Bridge to Survivorship." Dr. Shad was named the first Amey Distinguished Professor. In addition to her work at Georgetown, Dr. Shad dedicates significant time to improving the survival rates in children with cancer in developing countries. Dr. Shad has been instrumental in establishing palliative care and pediatric cancer programs in several Middle Eastern and Asian countries.



**Dr Fenton Howell** is a Director of Public Health with the Health Service Executive-Population Health Directorate in Ireland. He is also Clinical Senior Lecturer in the Department of Public Health and Primary Care, TCD. Dr Howell qualified in medicine from University College Dublin, obtained his Masters Degree in Public Health and Membership of the Faculty of Public Health Medicine. He is a Fellow of the Faculty of Public Health Medicine, a Fellow of the Royal College of Physicians in Ireland and a Fellow of the UK Faculty of Public Health. He is the current President of the Royal Academy of Medicine in Ireland. He is the Chair of the Ireland-Northern Ireland-National Cancer Institute Cancer Consortium Prevention Working Group. He is a former Dean of the Faculty of Public Health Medicine in Ireland, and a former President of the Irish Medical Organisation. He is a longstanding Board member of ASH Ireland and is a Board member of the Research Institute for a Tobacco Free Society. He is a tireless advocate of smoking cessation.



**Patrick Johnston** received his degree in Medicine from UCD in 1982. He pursued his initial training in the Mater Hospital, during which time he attained his doctoral degree. He obtained a fellowship at the National Cancer Institute, USA where he pursued further training in medical oncology and his post-doctoral studies in molecular pharmacology and drug development. He received the Young Investigator Award from the American Society of Clinical Oncology and the Technology Award from the National Cancer Institute. In 1996, he was appointed Professor of Oncology at Queen's University Belfast and since then he has led the development of a comprehensive cancer centre for Northern Ireland encompassing a state-of-the-art Clinical Cancer Centre and a major cancer research complex - the Centre for Cancer Research and Cell Biology at Queen's - of which he was Director until August 2007. This interdisciplinary research centre has as its major emphasis translational research, and houses over 300 researchers from all over the world. He was appointed Dean of the School of Medicine and Dentistry and Director of the Institute of Health Sciences at QUB in September 2007.



**Tony O'Brien** was appointed Chief Executive of the National Cancer Screening Service Board on its establishment on 1st January 2007. He is deputy director of the National Cancer Control Programme. He was Director of BreastCheck the National Breast Screening Programme since 2002 and has led the national expansion of the Programme. He was a member of the Interim HSE Change Management Team and is a primer mover in the implementation of the National Plan for Radiation Oncology. He was previously Chief Executive of both the UK and Irish Family Planning Associations.



**Thomas H Lynch** is a consultant urological surgeon in St. James's Hospital Dublin and senior lecturer in surgery at Trinity College, Dublin. He has a special interest in Urological Oncology and has an active interest in laboratory based prostate cancer research. He is a graduate of University College Galway and has trained in urological oncology in the United States and the United Kingdom. He was formerly a consultant in Belfast City Hospital. He has a regular column in the Health Supplement of the Irish Times.




**Kathleen O Meara** is Head of Advocacy and Communications at the Irish Cancer Society. She is a former member of Seanad Eireann, RTE journalist and Ministerial Adviser. She served in Seanad Eireann for the Labour Party. She was Labour's front bench spokesperson on Childcare and Labour Whip in Seanad Eireann. Before entering politics, Kathleen O'Meara worked as a journalist in RTE and as a Ministerial Adviser to Eithne Fitzgerald She retired from politics last year following the General Election and joined the Irish Cancer Society as the society's first Head of Advocacy and Communications.



**Owen Smith** is a Consultant Paediatric Haematologist, at Our Lady’s Hospital for Sick Children, Dublin, and is Professor of Haematology at TCD. His active research areas of interest include: childhood and adolescent leukaemias and lymphomas, bone marrow failure syndromes; the molecular and cellular basis of the inflammatory – coagulation interface in human disease. In 2001 he was awarded;the Graves Medal by the Royal Academy of Medicine and Health Research Board for his research into the pathobiology and novel therapeutic strategies in severe sepsis that had received international acclaim. In 2006, he was awarded the St Luke’s Medal for his work on improving outcomes in adolescent cancers with specific reference to the leukaemias and lymphomas.



**John V. Reynolds** is Professor of Surgery and Head of the Department of Surgery, Trinity College Dublin. He is Scientific Director of the Cancer Clinical Trials Office at St. James’s Hospital. He currently is the Regional Director of the Cancer Strategy Group for the HSE South Western Area and has managed Cancer Audit Systems and development of clinical guidelines for cancer care. He has held Fellowship positions with the University of Pennsylvania and Wistar Institute, Philadelphia and at Memorial Sloan-Kettering Cancer Centre, New York. He was Senior Lecturer at St. James’s University Hospital in Leeds and at St. Mary’s Hospital and Imperial College, London. His clinical interest is in cancers of the oesophagus, and stomach, and in Barrett’s oesophagus and GIST tumours. His research interest is in using modern molecular biology techniques to uncover pathways of cancer development in the oesophagus, in obesity and cancer, and in understanding why patients with oesophageal cancer respond or are resistant to chemotherapy and radiation therapy



**Davida De La Harpe** is Assistant National Director of Population Health in the HSE and heads up the function of Health Intelligence in the Directorate of Population Health. This function includes developing health information capabilities and supporting evidence based health care and research. She worked as a specialist in Public Health Medicine in a number of former health boards and was a Senior Lecturer in Evidence Based Healthcare in the RCSI. She has published in a number of areas including cardiovascular disease management, infectious disease management and implementation of evidence based health care. She has a particular interest in international health and development of equitable and sustainable solutions to public health issues by shared learning between Ireland and other countries.



**Mary Jackson** joined the Department of Health and Children (DoHC) in 1988, with qualifications in applied biology and laboratory science. She acquired a B.A. in Public Health Management with a health economics focus in 1994. During her tenure with the DoHC, she has worked in the Health Promotion, Community Health, and Blood Policy divisions; in 2007, she was assigned as Principal Officer of the Cancer Policy Unit. Ms. Jackson and her unit work closely with the NCCP and other health agencies in Ireland, eg National Cancer Registry, the National Cancer Screening Service, and the Health Research Board, in shaping an appropriate health response to cancer control issues. Throughout her career, she has been actively involved in supporting a multi-disciplinary approach to tackling health related issues.



**Paul Browne** is a Consultant Haematologist at St James’s Hospital. Following his training at Trinity College Dublin and St James’s Hospital, he went to the University of Minnesota and completed his haematological training and was on the faculty of the University. His research interests are in haematological malignancies with a particular emphasis on myeloma. He recently received the St Lukes Medal for Cancer Research and is the current Chair of the Irish Cooperative Oncology Research Group (ICORG).




**Tom Keane** is a graduate of University College Dublin. He trained in Radiation Oncology at the Princess Margaret Hospital in Toronto. He was appointed Professor, Dept. of Radiation Oncology, University of Toronto. He took up the position of Provincial Radiation Therapy Programme Leader in the British Columbia Cancer Agency in Vancouver, where he was Professor and Head of the Division of Radiation Oncology and Developmental Radiotherapeutics at the University of British Columbia. His areas of expertise include radiation oncology (head and neck, gastrointestinal cancer), Radiation Therapy program planning, health care leadership and clinical process management. He was a key figure in the overhaul of cancer services in British Columbia and has been seconded by the British Columbia Cancer Agency to the HSE to implement the National Cancer Control Strategy and transform the provision of oncology services in Ireland.



**Dermot Kelleher** graduated in Medicine from TCD and completed specialist training in Gastroenterology in Dublin. He subsequently received a Fogarty Scholarship for a research fellowship at University of California San Diego. He was appointed as a Wellcome Senior Fellow in Clinical Science at TCD and was subsequently appointed as Professor of Clinical Medicine in 2001. Professor Kelleher’s research has focused on the cell biology of immune responses both in terms of basic lymphocyte function and in relationship to mucosal immunology. Prof Kelleher is inaugural director of the Institute of Molecular Medicine, a TCD facility at St James’s Hospital. More recently, he has been successful in obtaining funding for a Wellcome Trust HRB funded Clinical Research Centre at St James’s Hospital. He was also the PI for the development of a 4 year PhD programme in Molecular Medicine funded by the HRB. He is a founding member of Opsona Theapeutics, a campus company at TCD .



**Joe Simone** is Director of the University of Florida-Shands Cancer Center. He has served as president of Simone Consulting Company, which advises organizations on cancer program quality and development. He is Clinical Director Emeritus of the Huntsman Cancer Institute and Professor Emeritus of pediatrics and medicine at the University of Utah School of Medicine. He served as physician-in-chief of the Memorial Sloan-Kettering Cancer Center in New York City. Before joining Memorial Sloan-Kettering, he spent virtually his entire medical career at St. Jude Children’s Research Hospital in Memphis, where he served as director from 1983 to 1992. In his years there, he played a leadership role in the development of curative treatments for childhood leukemia and lymphoma. Dr. Simone has served as chairman of the National Cancer Policy Board of the Institute of Medicine, which has published several reports on the quality of cancer care. He was the founding medical director and chairman of the National Comprehensive Cancer Network.



**Luke Clancy** is a physician with an international track record in the area of smoking and health and on causes; management and prevention of respiratory diseases particularly air pollution, asthma, cancer and tuberculosis. His research on the increased mortality associated with the Dublin smog led to the ban on burning of bituminous coal and made a significant contribution to world air pollution literature. His current focus is on the prevention of smoking related diseases by advocacy and research. As Chairman of the Board of ASH Ireland he played a significant role in the debate on anti-tobacco legislation in Ireland. In December 2003 Prof Clancy was appointed to the post of Director General of the Research Institute for A Tobacco Free Society (RIFTFS), which supports the development of a tobacco free society by engaging in research in all aspects of tobacco control from a public health perspective.




**Enda Connolly** was appointed as Chief Executive of the Health Research Board in June 2008. Since then, his main focus has been to strategically position the organisation to deliver a step change in health research. His aim is to increase research capacity in the health services and create an environment that can absorb new innovations, deliver better service and improve patient care. Prior to this, Enda spent more than 30 years in IDA Ireland, where he played a pivotal role in leading change, developing strategy, building stakeholder confidence and securing significant foreign direct investment. He was instrumental in developing the agency’s R & D Strategy following his return from five-year assignment as Head of IDA’s marketing operations in North America.




**David Khayat** is Professor of Medicine and Head of Medical Oncology at the Hospital Pitié-Salpêtrière, Paris, France. He gained his medical degree at the University of Nice and completed his PhD in tumour immunology at the University Pierre and Marie Curie, Paris. He is also Adjunct Professor of Medicine in the Department of Breast Diseases at the MD Anderson Cancer Center, Houston, United States. He was the President of the French National Cancer Institute (INCa) from 2004-2006 and is now Honorary President of this Institute. He organised the French Federation of Medical Oncologists (FFOM) and was elected its first President, a post he held until 2001. He set up the Master of Excellence of Medicine in Oncology programme. He is Professor Emeritus of several institutions, including the Suzhou Institute for Onco-haematology in China and the Matsumoto University in Japan. He received the American Association for Cancer Research public service award in 2000. His main research interests include predictive factors of response to immunotherapy in melanoma patients and the development of phase I and II studies testing new agents in breast, colorectal, and lung and melanoma. His centre is involved in the evaluation of new drugs and new targets in the treatment and diagnosis of cancer.




**Anna Gavin**, Graduate of Queen’s University Belfast Medical School and London School of Hygiene and Tropical Medicine is a Consultant in Public Health Medicine and Senior Lecturer, Epidemiology & Public Health, Queen’s University Belfast. She is Founding Director of the N. Ireland Cancer Registry which has undertaken population based audits of the major cancer sites. She is Chair of Action and Smoking Health (ASH) Committee for Northern Ireland




**Shane Allwright** is an Associate Professor of Epidemiology in the Department of Public Health and Primary Care, Trinity College Dublin, a Fellow of Trinity College Dublin and a Fellow of the UK Faculty of Public Health. Her research interests include health effects of active and passive smoking and of alcohol misuse; evaluation of tobacco and alcohol control policies; and prisoner health. She was the lead investigator on a study of the impact of the ban on the respiratory health of bar workers (All Ireland Bar Study) and chaired the report to the Minister for Health and Children entitled “Report on the health effects of environmental tobacco smoke (ETS) in the workplace” that was critical to the introduction of the Irish smokefree workplace legislation.



**Valerie Beral** studied medicine at Sydney University, Australia. She spent almost 20 years at the London School of Hygiene & Tropical Medicine working in the Department of Epidemiology. In 1988 she became the Director of the Cancer Research UK Epidemiology Unit in Oxford. Major focuses of her research include the role of reproductive, hormonal and infectious agents in cancer. She has published widely on the incidence of cancer in people infected with HIV, and is principal investigator of the International Collaboration on HIV in cancer, which brings together worldwide data on the subject. She has published in leading international journals including the Lancet and The British Medical Journal.



**Anthony Staines** was appointed as the first Professor of Health Systems Research in the School of Nursing in DCU in 2007. Prior to this he spent a decade in UCD in the School of Public Health. He works on haematological disease epidemiology, especially multiple myeloma. He is the Irish lead for the Epilymph project, and a member of the Interlymph consortium and one of the founders of the International Multiple Myeloma Consortium. He works on the uses of information in many different settings, including health service funding, health service planning, environmental policy, and infectious disease epidemiology.




**Jane Wardle** did her undergraduate degree in psychology at Oxford University and her PhD and clinical psychology training at the Institute of Psychiatry. After working in a combined academic/clinical post for several years, she became director of the Cancer Research UK Health Behaviour Research Centre and Professor of Clinical Psychology at University College London. The Centre was set up to investigate determinants and change of behaviours related to cancer prevention. in i) smoking, ii) obesity and food choice, and ii) early detection of cancer.



**Des Carney** completed his undergraduate training in Unviersity College Dublin. He became a Fellow in Medical Oncology at the NCI Navy Medical Oncology Branch Bethesda USA. After completing his fellowship, he joined the staff at this branch. He was a key figure in devising technique for the isolation, establishment and characterization of cell lines of human lung cancer, in particular small cell lung cancer. In 1984 Prof Carney was appointed Consultant Medical Oncologist at the Mater Misericordiae Hospital Dublin He is involved in both clinical work and trials, and his laboratory research interest continues with special emphasis on malignant lymphomas and breast cancer. He has been a member of the International Association for the Study of Lung Cancer (IASLC) since 1980 and a member of the Board of Directors since 1994. In 1997 Professor Carney hosted the 8<sup>th</sup> World Lung Cancer Congress in Dublin. In 2000 Professor Carney was awarded the IASLC Merit Award. In 2007 the British Thoracic Oncology Group (BTOG) Achievement Award was

presented to Professor Carney for his contributions to the both the treatment and biology of lung cancer, in particular small cell lung cancer.

In November 1993, **Barbara Cosgrave** left behind a varied career in the business world and, together with Professor Des Carney, founded ARC Cancer Support Centre in Eccles Street. Standing for **A**ftercare **R**esearch **C**ounselling, ARC was set up to provide support and counselling for people affected with cancer, their family members and friends, no matter where they live or where they are treated. Barbara was the Minister's nominee to the second National Cancer Forum representing the layperson and the voluntary sector. She acted as an adviser in the establishment of Cork ARC Cancer Support House. With the backing of the Department of Health and Children and the HSE she spearheaded the drive to establish an ARC House on South Circular Road (opening Autumn 2009).



**Mairéad Lyons** has recently joined the Irish Cancer Society from a Government advisory position as Director of the National Advisory Committee on Drugs. Mairéad has a long and varied career in healthcare in the public, voluntary and private sector. Whilst originally trained as a general nurse, Mairéad went on to train in Public Relations, in Health Promotion and in Health Service Management. Mairéad will lead and manage the Society's programme and service areas, delivering on existing programmes around prevention and early detection, and developing innovative new services for those affected by cancer. These new programmes and services will deliver on our goals which are focused on cancer prevention, early detection and fighting cancer.

**Sonya Collier** is a Principal Clinical Psychologist in St James's Hospital, Dublin. She is a graduate of the School of Psychology, Trinity College Dublin, where she undertook both her undergraduate degree and her clinical doctorate training. Together with Dr Anne-Marie O'Dwyer, Consultant Psychiatrist, she established the HSE award winning Psycho-Oncology Service in St James's hospital in 2002. She is a lecturer and supervisor on the Doctorate in Clinical Psychology Training Programme in TCD and on the Cognitive Behavioural Therapy Masters Programme. Her clinical and research interests are in the development of cognitive behavioural interventions for alleviating distress caused by cancer and / or its treatment, investigating the psychological impact of working in cancer on staff and the creation of psych-oncology training programmes.



**Paul D'Alton** is Senior Clinical Psychologist and Head of the Psycho-oncology Service at St Vincent's University Hospital, Dublin, Ireland. The Psycho-Oncology Service has a clinical, teaching & research remit across the cancer services of the hospital. Paul completed his clinical training at TCD and more recently advanced training in Mindfulness Based Stress Reduction at the University of Massachusetts Medical School. St Vincent's has developed considerable expertise in the area of Mindfulness and Oncology with over 120 patients attending the Mindfulness Based Cognitive Therapy programme over the last 3 years. Paul currently leads an extensive staff training programme aimed at the early identification and management of distress among cancer patients. He lives in Dublin City, is a committed cyclist & a reasonable cook!



**Frank Gannon** was appointed as SFI Director General by the SFI Board in 2007. Prof Gannon joins SFI from his position as Executive Director of the European Molecular Biology Organisation (EMBO) and Senior Scientist at the European Molecular Biology Laboratory (EMBL), in Heidelberg, Germany; where he worked since 1994. Prof Gannon was Director of the National Diagnostic Centre and Associate Professor in the Department of Microbiology at University College Galway, Ireland. He was a post-doctoral fellow at the University of Madison Wisconsin, USA and Chargé de Recherche in INSERM at the University of Strasbourg, France when he moved back to Galway. His major research interest is the expression and functional regulation of Estrogen Receptor which plays a major role in breast cancer and osteoporosis. These studies have provided leads to novel treatments or therapeutic approaches to these and other cancers. He was elected as a Member of the Royal Irish Academy in May 2008 and was awarded a Doctor of Medical Science by Queen's University Belfast in June 2008.



**Pierre Chambon** is Honorary Professor at the College de France (Paris), and Emeritus Professor at the Faculté de Médecine of the Strasbourg University. He was Founder and former Director of the IGBMC, and also Founder and former Director of the Institut Clinique de la Souris (ICS/MCI), in Strasbourg. He is a world expert in the fields of gene structure, transcriptional control of gene expression. During the last 25 years his studies on the structure and function of nuclear receptors has changed our concept of signal transduction and endocrinology. By cloning the estrogen and progesterone receptors, and discovering the retinoic acid receptor family, he markedly contributed to the discovery of the superfamily of nuclear receptors and to the elucidation of their universal mechanism of action. The discoveries of Pierre Chambon have revolutionized the fields of development, endocrinology and metabolism, and their disorders, pointing to new tactics for drug discovery, and finding important applications in biotechnology and modern medicine. These scientific achievements are logically inscribed in an uninterrupted series of discoveries made by Pierre Chambon over the last 45 years: discovery of PolyADPribose contribution to elucidation of chromatin structure: the Nucleosome, discovery of animal split genes, discovery of enhancer elements, discovery of multiple promoter elements and their cognate factors. He has received numerous international awards, including the 2004 Lasker Basic Medical Research Award. He is author of more than 900 publications. He has been ranked fourth among most prominent life scientists for the 1983-2002 period.



**Joan Kelly** is Nursing Services Manager in the Irish Cancer Society and her role involves managing a range of nursing services aimed at helping cancer patients and their families. These include; Cancer Information Services, incorporating the National Cancer Helpline, developing patient education booklets and web information; a National Night Nursing Service for seriously ill cancer patients in the community; continuing education in cancer care for non-specialist nurses. She also manages the Oncology Liaison Nurses grants and Daffodil Grants for Home Care/Palliative Care Nurses. She has been involved in the IANO National Executive Committee and has held the position of President and Secretary.



**Margaret Codd** is presently the Nurse Manager for the Clinical Haematology, Oncology, Palliative care and Hereditary Coagulant Disorders (HOPE) Directorate in St. James's Hospital. She has extensive clinical and managerial experience including ICU Facilitator and Cancer Nurse Co-ordinator for Head and Neck Cancer patients. She was a member of the 2nd National Cancer Forum and the Advisory Group for the implementation of the National Cancer Control Programme. Margaret hopes to complete an MSc in Creative Leadership and Organisational Learning (RCSI) later this year.



A registered psychiatric and general nurse, **Paul Gallagher** joined the corporate management team of St. James’s Hospital, as Director of Nursing in August, 2006. He has responsibility for overseeing the Nursing Practice Development Unit, undergraduate, postgraduate and general education requirements for over 1,650 nursing and healthcare assistant staff. Paul is also responsible for over-seeing the recruitment, retention and development of the nursing profession at St. James’s. He has obtained a great deal of clinical and managerial experience in the Intensive Care setting both in Dublin and North America. He was Assistant Director of Nursing at Beaumont Hospital, Dublin, for 7 years prior to his current appointment. He holds an MBA from The Smurfit Business School, UCD.



**Janice Richmond** completed Nurse training in 1996 and since then has held various positions mainly within cancer care to include staff nurse, practice development nurse, and clinical nurse specialist. Current employment since 2006 is as an advanced nurse practitioner. This was the first accredited oncology ANP in Ireland. While the current job utilises skills of advanced nursing practice, the role also encompasses leading the oncology nursing team, audit of service provision, post registration and post-graduate education and performance of research.



**Eilís McCaughan** is a Reader in Cancer Care in the Institute of Nursing Research at the University of Ulster. Following a career in cancer nursing, she has led developments in education programmes for cancer nurse specialists. She is actively involved in cancer care developments at local and national levels. Eilís leads the ‘Special Interest Group’ for nursing and allied healthcare professionals within the Cancer RRG, R&D, NI. She also is the theme leader for cancer care research at the University of Ulster. Her current research programme of work involves a series of studies exploring and meeting the needs of men with cancer.



**Mairéad Ní Chonghaile** spent four years on a Medical & Haematology ward in Dartford, England. After moving to the Hammersmith Hospital, she received the ENB A27 from Thames Valley University. On returning to Ireland she worked as on the National BMT Unit as a staff nurse while completing her Bachelor of Nursing Studies in Dublin City University and has completed her MSc in TCD. Currently she is BMT co-ordinator for the national adult BMT programme and was involved in the development of the Late Effects service. She is an active member of the Haematology Association of Ireland Nurses’ Group, EBMT Nurses’ Group (EBMT NG), and ONS. She has been secretary of the EBMT NG and is currently chair of the EBMT NG Scientific Committee, as well as the EBMT NG nursing representative to JACIE.




In 1991, **Tracy Council** began an art therapy program for the Division of Pediatric Hematology-Oncology at Georgetown University Medical Center’s Lombardi Cancer Center. That program has grown into Tracy’s Kids, for which she serves as Program Director, advising, training and supporting 6 Art Therapists who implement art therapy programs for Pediatric Hem-Onc patients and their families in treatment centers in Washington, DC. She also leads art therapy research with childhood cancer survivors in Georgetown’s Pediatric Hematology-Oncology Survivorship Clinic. In 2007, Ms. Council participated in the Middle East Cancer Consortium (MECC), and from that experience her organization developed an International Art Exchange among pediatric hematology-oncology patients in the US and the Middle East. “The day I will never forget” is on display at this conference, before it travels to the participating countries.



**David Lloyd** holds a BSc in Applied Chemistry and a PhD from the School of Chemical Sciences in Dublin City University. Dr Lloyd spent three years as a post-doctorate in the School of Pharmacy, Trinity College before taking a position in De Novo Pharmaceuticals in Cambridge, UK, where he headed the company’s ligand-based design discovery programme. He returned to Trinity in 2004 to take up a faculty appointment in the School of Biochemistry and Immunology as Hitachi Senior Lecturer in Advanced Computing. In June 2005 Dr Lloyd was appointed as Trinity’s first Associate Dean of Research with a brief to foster and build external research interactions for Trinity, and in July 2007 he became the Dean of Research for the University.



**Corrado Santocanale** obtained his Ph.D. degree in Cellular and Molecular Biology in 1993 from the University of Milan, Italy. His early studies focused on the biochemical and genetic characterization of proteins involved in DNA replication. As a postdoctoral fellow at the Imperial Cancer Research Fund, London, he studied the mechanisms that control DNA replication origin function. In 1999 Prof. Santocanale joined Pharmacia Upjohn where led a cross-disciplinary preclinical drug discovery programme. This resulted in the discovery of the first Cdc7 kinase inhibitor that directly blocks DNA replication origin firing and to its development as an experimental drug for treating human cancer. In September 2007 was appointed as Chair of Molecular Medicine at NUI Galway. His research focuses on understanding the molecular mechanisms of DNA replication in cancer cells and their exploitation for therapeutic purposes.




**Damian O Connell** is Clinical Research Group Head in the Pfizer Sandwich Research Business Unit. He has previously been Head of Experimental Medicine at the Pfizer Global Research & Development site in Sandwich. Immediately prior to this position, he was employed by Warner-Lambert as International Drug Director (Cardiovascular & Clinical Pharmacology) with responsibility for conducting all Phase 1-2a clinical studies outside the USA. He has MB BAO BCh, PhD & BSc degrees from the National University of Ireland, has been an Internal Medicine Faculty member of The University of Virginia Health Sciences Center as well as being a member of the Clinical Pharmacology & Therapeutics Department at University College Cork. He started his career in the Industry in 1998 with Elan Pharmaceuticals as Director of Clinical Research (US) Damian is currently Chairperson of the Board of Molecular Medicine Ireland.



**Rod Hubbard** has spent his academic career at the University of York, focussing on analysis and exploitation of protein structure. In the 1980s, he developed molecular graphics and modelling methods. In the 1990s, he helped to build (and directed) the Structural Biology Laboratory at York as a major centre, with over 80 scientists studying structure and function of proteins. His personal research interests have focused on understanding the relationship between structure, mechanism and function in various protein systems (including proteases, nuclear receptors and kinases) and on how to exploit structural information in ligand and drug discovery. Since 2001, he has spent some of his time at Vernalis, where he helped establish and apply structure-based drug discovery methods including virtual screening and fragment based lead discovery. This has generated molecules now in clinical trials and pre-clinical development.



**John Fox** joined Merrion Pharmaceuticals last year as Chief Development Officer from Hunter Fleming, an early stage R&D company he co-founded in 1999 and where he served as Chief Operating Officer. Dr Fox held a variety of clinical R&D positions in Shire Pharmaceuticals. As Group Planning Director, he covered planning and new project assessment for constituent companies within Shire and was responsible for project implementation in the United States, Europe and Japan. Before joining Shire, Dr Fox held clinical research and development roles in Eli Lilly & Co Ltd and as a Research Officer in the Department of Therapeutics and Pharmacology, Queens University Belfast. He holds a PhD and a BSc in Biochemistry from Queens University Belfast, as well as an MBA from Henley Management College.



**Donal Hollywood** is Marie Curie Professor of Clinical Oncology at TCD and Head of the Academic Unit of Clinical and Molecular Oncology. His research interests include the investigation of novel molecular therapeutics and their clinical integration with biologically optimized radiation therapy. He was Chair of the National Expert Group on Radiation Oncology and is currently the Director / Advisor to the National Programme for Radiation Oncology (NPRO) and National Cancer Control Programme (NCCP). He was the founder of the ESTRO molecular oncology education program. He is a member of the NCI-All Ireland Consortium Implementation Group, and Chair of the Information Technology Group. He is Chair of the ESTRO Clinical Committee and has participated in a number of strategic reviews of programmatic cancer service development including the US Presidents Cancer Panel. He has received a number of awards including a Fulbright Scholarship, the Lilly Research Scholarship and the St Luke's Medal.



**Frank Sullivan** is Director of the Department of Radiation Oncology, at Galway University Hospital (GUH). He holds the Chair of Radiation Oncology, NUI Galway. Prof. Sullivan was formerly the Chairman (Acting) of the Radiation Oncology Branch (ROB), at the National Cancer Institute (NCI), the Cancer Center Director for Holy Cross Health Cancer Institute, Silver Spring MD, as well as CEO and Medical Director of Maryland Regional Cancer Care (MRCC). He holds Adjunct Faculty appointments at the NCI and Georgetown University. He now has an active interest in prostate and lung cancers, as well as novel radiation techniques including IMRT, and stereotactic radiosurgery. Dr. Sullivan is a Principal Investigator on the International Early Lung Cancer Action Project Trial (I-ELCAP), a seminal study in the use of a novel imaging protocol to effectively detect lung cancers. He was recently appointed by Mary Harney TD, Minister for Health and Children, to serve on the newly constituted National Cancer Screening Board, Prof Sullivan has helped co-develop several international cancer projects, including the NCI-All Ireland Cancer Consortium.



**Anne Hansen Ree** graduated from Faculty of Medicine, University of Oslo, where she further received a PhD degree in molecular tumor biology. She completed a postdoctoral project on metastasis biology at the Norwegian Radium Hospital, where she next served as fellow of clinical oncology and researcher in molecular radiation oncology, completing her specialist training in medical and radiation oncology. She was attending physician at Division of Cancer Medicine and Radiotherapy, Norwegian Radium Hospital, until 2006, when she was appointed professor of oncology at the University of Oslo. She is also head of the Department of Oncology at Akershus University Hospital. Her main scientific interests are focused on molecular targeted therapies in combination with radiotherapy and the prediction of treatment response. In recent years, the group has systematically developed new concepts of molecular targeting therapeutics in radiotherapy

from experimental *in vitro* and *in vivo* tumor models to clinical phase I-II trials. Ree’s scientific work was recently honored with the national *Blix’ Family Foundation Award to a Younger Medical Scientist in Cancer Research*.



**Michael Baumann** graduated in medicine from the University of Hamburg and was a Research Fellow at Harvard Medical School, USA. He joined the Clinic of Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Technology (TUD), Dresden as Consultant Radiation Oncologist where he was also Head of Experimental Radiation Oncology and Radiobiology. He was appointed as Acting Director and Professor at the Department of Radiotherapy, the University of Saarland, Homburg (Germany) in 1999, and has served as Vice Director of the Clinic of Radiotherapy and Radiation Oncology at the TUD since the year 2000, and Director of the Experimental Center of the


Medical Faculty since 2001. His work has been recognised through numerous academic awards and honours. He sits on several committees and has also served many learned societies such as the European Society for Therapeutic Radiology and Oncology (ESTRO) for which he was President from 2003-2007. He is currently President of ECCO – the European CanCER Organisation.



**Rosemary O’Connor** is Professor of Cell Biology and the Head of the Department of Biochemistry at University College Cork, Ireland. Prior to returning to Ireland she worked in the USA and Germany in both academia (the Institute of Pathology of the University of Wuerzburg, Germany and the Wistar Institute, Philadelphia) and industry (Immunogen, Inc., Cambridge, Massachusetts) where her contributions led to new drug discovery and clinical trials. Since taking up her post at University College Cork in 1997 she has helped to establish the Biosciences Institute, launch a structured PhD training program in cancer biology, and establish a research programme. The primary focus of her present research is on Insulin like growth factor signalling, particularly in cancer, although applications extend to most branches of biology. She was awarded the Irish Area Section Medal by the Biochemical Society in 2007.



**Adrian Bracken** is a newly appointed Lecturer at The Smurfit Institute of Genetics, Trinity College Dublin and the Adelaide and Meath Incorporating the National Childrens Hospital, Tallaght. During his post-doctorate years he gained an international reputation for using Cancer Transcriptomics to explore cancer pathways and identify novel prognostic and therapeutic targets. He is a PhD graduate of Trinity College Dublin (2000) and has held fellowships at The European Institute of Oncology, Milan, Italy and The Biotechnology and Research Innovation Centre at The University of Copenhagen, Denmark. Currently he is settingup his own independent research group at The Smurfit Institute of Genetics, TCD.



**Lisa Coussens** is a Professor in the Pathology Department and Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. Her lab focuses on the role of immune cells and leukocyte proteases as critical regulators of skin, lung and breast cancer development. She is interested in understanding the molecular mechanisms that regulate leukocyte recruitment into neoplastic tissue and subsequent regulation those leukocytes exert on evolving cancer cells. The long-term goal of this work is to translate basic observations made in the mouse, toward rational design of novel therapeutics whose aim will be to block and/or alter rate-limiting events critical for solid tumor growth or maintenance in humans. Dr. Coussens received her Ph.D. from UCLA in 1993, and completed her postdoctoral fellowship in Cancer Biology at University of California, San Francisco in Douglas Hanahan’s laboratory. Since

establishing her own laboratory in 1999, Dr. Coussens has received the prestigious Gertrude B. Elion Award from the American Association of Cancer Research (AACR), the Mallinckrodt Award for Medical Science and a V Foundation Scholar Award for her novel discoveries regarding the role of matrix metalloproteinases (MMPs) and mast cells in epithelial cancer development. More recently, Dr. Coussens was awarded an *Era of Hope Scholar Award* from the Department of Defense Breast Cancer Research Program to support her investigation of chronic inflammation as a regulator of breast carcinogenesis.




**Mike Lenardo’s** is Chief of the Molecular Development Section at the National Institutes of Health. His laboratory investigates the molecular regulation of T lymphocytes, particularly as it relates to immunological tolerance, apoptosis, cancer and autoimmune diseases such as multiple sclerosis, myasthenia gravis, and similar diseases. His laboratory uses both molecular biology and cellular immunology techniques to pursue these investigations. Their goal is to understand the pathogenesis of autoimmunity from the vantage point of T-cell regulation as well as develop novel means of immunomodulation of these diseases.



**Cormac Taylor** is Associate Professor of Cellular Physiology at University College Dublin. Prior to his appointment at UCD, he did a post-doctoral fellowship at Harvard Medical School. Current research is directed towards expanding our understanding of the mechanisms by which low oxygen (hypoxia) regulates transcriptional events in the context of inflammatory disease and cancer. His research is focused on the regulation of inflammatory gene expression in response to hypoxia and the modifications of transcriptional regulators which underlie such events with a particular focus on the NF-kappaB pathway.



**Martin Bradley** is the Chief Nursing Officer in Northern Ireland. Prior to taking up this post in November 2005, Martin was Director of the Royal College of Nursing, Northern Ireland. His background is in general and psychiatric nursing, nurse education, and administration in the Health and Social Services. He is a Director of the Northern Ireland Association of Mental Health, a mentor for the King’s Fund Nurse Leadership programme, a member of the steering committee of the Florence Nightingale Foundation and the Florence Nightingale Museum at St Thomas’ Hospital, London. He is a past member of the UK Central Council for Nurses and Midwives, and a former member of the BBC Broadcasting Council. He also is the current chair of the All Ireland Cancer Nurses group. He has a particular interest in community development, public health, targeting health and social need, primary care and practice development. He is a visiting Professor of Nursing at the University of Ulster and in 2000 was made a Fellow of the Royal College of Nursing for his services to Nurse Education and Higher Education



**Jessica Corner** is Professor of Cancer and Palliative Care and Head of the School of Health Sciences at the University of Southampton. Her research interests focus on the improvement of care for people affected by cancer, systems and strategies for improving the experience of cancer and advanced practitioner roles in health care. Prof Corner leads a research programme to improve the care of people affected by cancer. She was a member of the Department of Health Cancer Reform Strategy for England, chairing the Patient Experience working group; she continues to work closely with the Department of Health to deliver the National Cancer Survivorship Initiative. As Chief Clinician for Macmillan Cancer Support, she advises on Macmillan’s forward direction, vision and strategy, and for representing Macmillan externally.

Her work involves strengthening existing and forging new alliances, and championing innovation in cancer services.



**John McCormack** was appointed CEO of the Irish Cancer Society in October 2002. He was formerly Company Secretary and Financial Controller with the Society, is a member of the Institute of Certified Public Accountants in Ireland and holds an MBA from Dublin City University. In 1991, he founded the Irish Charities Tax Reform Group which has lobbied successfully for the introduction of tax relief on corporate donations. One of Mr McCormack’s key areas of interest is men’s health and in April 2006, he led the launch of Action Prostate Cancer (APC) and the Prostate Cancer Information Service (Freefone 1800 380 380), to complement the Society’s already hugely successful Action Breast Cancer programme. Since its launch, the Prostate Cancer Information Service (PCIS) has responded to over 10,000 enquiries from men (and their partners). Mr McCormack was also instrumental in contributing to the success of the Society’s 2006 - 2008 lobbying campaign for the roll-out of a free nationwide cervical screening programme for all women aged 25 – 60 years. This screening programme titled, CervicalCheck, was launched by the National Cancer Screening Service (NCSS) in September 2008.



**Peter Selby** was appointed the Director of the Cancer Research UK Clinical Centre in Leeds in 1993 and is Professor of Cancer Medicine and Consultant Physician in St James’s University Hospital in Leeds. Peter was appointed to the Chair of Cancer Medicine at the University of Leeds in 1988 His clinical work is mainly with patients with urological cancers His current research programmes are in biotherapy examining cellular, vaccine and viral targeting for cancer therapy His other programme is in clinical cancer proteomics identifying novel biomarkers and new targets for cancer therapy led jointly with Professor Roz Banks. In 2000 Peter was appointed as Director of the National Cancer Research Network which was charged with providing a world class clinical infrastructure for clinical trials and other well designed studies. This was successful in increasing the clinical trials activity in the UK in cancer four-fold and providing a model which has

substantially influenced other developments for other aspects of health care in the United Kingdom and activities in many other countries across the world. In 2005 he became Joint Director of the United Kingdom Clinical Research Network which is now responsible for overseeing the development of clinical trials and other well designed studies within the NHS across all of healthcare. He was appointed Fellow of the Academy of Medical Sciences in 1998, and awarded a CBE in 2001 for services to cancer research and cancer care.

*CURRENT LIST OF CONFIRMED SPONSORS*



**We would like to take this opportunity to thank all of our sponsors whose generosity and support has made this Conference possible**